Coronavirus Update: Stage set for boosters for all three authorized vaccines
- ByMarketWatch-
Coronavirus Update: Stage set for boosters for all three authorized vaccines
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| NASDAQ | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
Coronavirus Update: Stage set for boosters for all three authorized vaccines
A Food and Drug Administration advisory committee voted unanimously Friday that allowing adults who were initially vaccinated with the Johnson & Johnson one-dose vaccine against...
The global tally for the coronavirus-borne illness climbed above 240 million on Monday, while the death toll edged above 4.9 million, according to data aggregated by Johns Hopkins...
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5...
The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the COVID-19 pandemic is still not over as the virus...
Europeans Vaccinated With AstraZeneca Should Be Able To Enter US, Says EUAuthored by Lorenz Duschamps via The Epoch Times,People who have received two doses of...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Buy | Strong Buy |
| Technical Indicators | Sell | Sell | Strong Sell | Buy | Strong Buy |
| Summary | Neutral | Neutral | Neutral | Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 206.50 | 207.00 | 196.80 | +8.50 | +4.29% | 578.16K | London | |||
| 552.00 | 563.50 | 550.50 | -9.50 | -1.69% | 351.27K | London | |||
| 7.25 | 7.25 | 7.25 | 0.00 | 0.00% | 21.58K | London | |||
| 6.95 | 6.95 | 6.95 | 0.00 | 0.00% | 261.65K | London | |||
| 368.60 | 373.60 | 360.60 | +4.40 | +1.21% | 846.20K | London | |||
| 51.00 | 50.60 | 50.60 | -1.00 | -1.92% | 2.52K | London | |||
| 55.00 | 55.00 | 55.00 | +0.50 | +0.92% | 31.99K | London | |||
| 86.50 | 88.00 | 88.00 | +0.75 | +0.86% | 9.50K | London | |||
| 1.45 | 1.45 | 1.45 | 0.000 | 0.00% | 1.36M | London | |||
| 383.00 | 385.50 | 365.00 | +15.50 | +4.22% | 1.93M | London | |||
| 1.275 | 1.275 | 1.275 | 0.000 | 0.00% | 720.34K | London | |||
| 458.00 | 461.00 | 453.00 | -1.00 | -0.22% | 26.64K | London | |||
| 1.20 | 1.20 | 1.20 | +0.1000 | +8.70% | 6.32M | London | |||
| 30.00 | 30.00 | 30.00 | 0.00 | 0.00% | 0.00 | Aquis Exchange | |||
| 198.00 | 198.00 | 198.00 | 0.00 | 0.00% | 0.00 | Aquis Exchange |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.